(Total Views: 520)
Posted On: 08/25/2023 1:02:59 PM
Post# of 154896
Lenvima that is being trialed with Keytruda is a VEGF inhibitor and of course leronlimab downregulates VEGF. Merck is mucking about knocking out small bits that are downstream of CCR5 when knocking down CCR5 is the key.
Elevated CCR5 is a biomarker for head and neck squamous cell cancer so the broader effects of a CCR5 blocker would be indicated as a treatment.
Elevated CCR5 is a biomarker for head and neck squamous cell cancer so the broader effects of a CCR5 blocker would be indicated as a treatment.
(16)
(0)
